hims novo nordisk - Search News

News

Novo Nordisk, Hims & hers health

CBS News on MSN · 2d

Novo Nordisk halts Wegovy sales on Hims & Hers, claiming "deceptive marketing" practices

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.

Investopedia on MSN · 2d

Hims & Hers Stock Plunges 35% as Novo Nordisk Ends Partnership, Citing 'Illegal' Practices

Hims & Hers Health shares tumbled nearly 35% Monday after Novo Nordisk said it is pulling out of its partnership with the digital pharmacy, citing "illegal" and "deceptive" practices.

Novo Nordisk Abruptly Ends Partnership with Hims, Claiming ‘Sham Compounding’ GLP-1 Drugs

The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent mandate. Hims pushed back against the accusation.

19hon MSN

Why Shares in Novo Nordisk Lost Weight Today

Shares in Denmark's pharmaceutical giant Novo Nordisk ( NVO -4.99%) were lower by 4% as of 11 a.m. ET today. The move comes ...

2don MSN

Hims & Hers Stock Drops More Than 30% After Novo Nordisk Breakup

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

1d

Long Island experts weigh in after Novo Nordisk ends deal with Hims & Hers over weight loss meds

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

3d

Hims & Hers Health Stock Is Tumbling Monday: What's Happening?

Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Monday after Novo Nordisk A/S (NYSE:NVO) terminated its ...

Zacks Investment Research on MSN6d

Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock lately despite its ...

3don MSN

Novo Nordisk shares fall as obesity pipeline faces investor scrutiny

Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results